CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (Zenith or the Company) announced today that the data from its Phase 2 Metastatic Triple Negative Breast Cancer (mTNBC) clinical trial combining ZEN-3694 + Pfizer Inc.s Talzenna (talazoparib) was highlighted at an oral session Optimizing Targeted Therapies in Advanced Breast Cancer: Building on Past Success. The discussant presented the novel concept of administering ZEN-3694, a bromodomain and extraterminal (BET) inhibitor (BETi), to sensitize resistant mTNBC tumors to talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), and the clinically meaningful response rate and manageable safety profile of the combination from the Phase 2 study. Selection of an abstract for an oral discussion is a very competitive process with only 24 of the more than 125 accepted abstracts selected for this presentation format. The poster can be viewed on Zenith Epigenetics website (Poster) and the discussion can be viewed on the ASCO website (Discussion).
The data from the Phase 2 trial demonstrate that the ZEN-3694 plus talazoparib combination regimen, with a clinically meaningful response rate of 32% in a defined population, has the potential for treating patients whose tumors do not harbor germline mutations in BRCA1/2, said Dr. Philippe Aftimos, a principal investigator and medical oncologist at The Institut Jules Bordet in Brussels, Belgium. This combination is active with a manageable safety profile and warrants continued clinical evaluation. Zenith has expanded the Phase 2 trial to continue to evaluate the combination in an additional 120 mTNBC patients (NCT03901469).
In conjunction with ASCO, Zeniths TNBC poster was also awarded the GRASP Advocate Choice Award and selected to be discussed at theGRASPPoster Walkthroughs. GRASP, which standsfor Guiding Researchers and Advocates for Scientific Partnerships,is a patient-led organization that brings together patients, clinicians, and researchers to exchange ideas and learn from each other to accelerate scientific breakthroughs. GRASP Poster Walkthroughs are small group discussions of selected posters presented at scientific conferences such as ASCO.
We are very pleased that the data from our mTNBC clinical study, conducted in collaboration with Pfizer, was well received and recognized at ASCO, said Don McCaffrey, CEO of Zenith Epigenetics. The combination regimen of ZEN-3694 + talazoparib has shown promising clinical activity in a mTNBC patient population with significant unmet need. We continue to advance this program toward registration and are committed to bring an important therapy to these patients.
About Zenith and ZEN-3694
Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need. Zenith Epigenetics is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for various oncologic indications, specifically:
About Triple Negative Breast Cancer (TNBC)
TNBC is an aggressive form of breast cancer with low survival rates. TNBC accounts for about 10-15%of all breast cancers and it differs from other types of invasive breast cancer in that it tends to grow and spread faster, has fewer treatment options, and tends to have a worse prognosis. The termtriple-negative breast cancerrefers to the fact that the cancer cells have only low or no amount of the receptors ER, PR, and HER2. Approximately 75,000 women in the US, Japan and the major EU countries are diagnosed with TNBC each year.
About ZEN-3694 + Talazoparib Combination
In the United States, talazoparib is currently approved under the brand name TALZENNA, which is a PARP inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. ZEN-3694, in combination with talazoparib, is being developed for targeting tumors that do not have a germline BRCA mutation which represent approximately 89% of TNBC tumors. Preclinical and clinical data has shown that BET inhibition may reduce the levels of DNA repair proteins such as BRCA1/2 and RAD51 and thus create synthetic lethality in wildtype BRCA1/2 TNBC tumors when combined with PARP inhibition.
For further information, please contact:
Investor Relations & Communications
Zenith EpigeneticsPhone: 587-390-7865Email: info@zenithepigenetics.comWebsite:www.zenithepigenetics.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the Companys development activities involving ZEN-3694 in combination with Pfizers PARP inhibitor Talzenna, and other targeted agents used in precision oncology, as well as other planned PARPi based combination therapy clinical trials in other tumor types. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our most recent MD&A which are incorporated herein by reference and are available through SEDAR at http://www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. Zenith disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
- The Role of Epigenetics and Contributing Impact of Stress, Multigenerational, and Developmental Factors in Opiate ... - Cureus - February 8th, 2024
- About Epigenetics | Johns Hopkins Institute of Genetic Medicine - November 16th, 2023
- What is Epigenetics? - Bruce H. Lipton, PhD - January 4th, 2023
- Why Epigenetics Contradicts Evolutionary Theory | Evolution News - December 18th, 2022
- Epigenetics in Psychology | Noba - November 24th, 2022
- Epigenetics: Definition, Mechanisms and Clinical Perspective - November 24th, 2022
- Researchers Find that Moms Pass On Additional Epigenetic Information To Their Children - WhatIsEpigenetics.com - October 13th, 2022
- Prestigious award advances OHSU research on impact of drug use over generations - OHSU News - October 13th, 2022
- Hoylake doctor launches test that detects diseases before they appear - Wirral Globe - October 13th, 2022
- Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Yahoo Finance - October 13th, 2022
- Understanding the Epigenetics of Childhood Trauma - Psych Central - October 4th, 2022
- Epigenetic therapy promotes spinal cord regeneration in mice following injury - RegMedNet - October 4th, 2022
- ORYZON to Give Updates on Corporate Progress in October - Yahoo Finance - October 4th, 2022
- InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone's Future Development for the Prevention and Treatment of Post COVID-19... - October 4th, 2022
- Cardio Diagnostics To Sponsor, Participate in the American Heart Association's 2022 Metro Chicago Heart Walk - Yahoo Finance - September 16th, 2022
- Book review: Daughters and the stories they carry - Yahoo News - September 16th, 2022
- Inherent Biosciences raises funding to expand fertility care though epigenetics - VatorNews - September 8th, 2022
- 10 wellness retreat trends to know about - Cond Nast Traveller - September 8th, 2022
- Spotlight: Women in Science: Dr. Judith Kassis on Pursuing the Unexpected - National Institute of Child Health and Human Development - September 8th, 2022
- Epigenetic Information Passed On to Offspring More Frequently Than Once Thought - Technology Networks - August 22nd, 2022
- New discovery shows you may inherit more from your mom than you think - EastMojo - August 22nd, 2022
- New Technology to Understand Cell Types and How Diseases Develop - Yale University - August 22nd, 2022
- Research Roundup: Fat Cell Hormone Slows Liver Tumor Growth and More Research News - BioSpace - August 22nd, 2022
- De-extinction? Plans to revive Tasmanian tiger triggers... - The American Bazaar - August 22nd, 2022
- Epigenetics in Health and Disease - PubMed - August 14th, 2022
- Clinical Epigenetics | Home page - August 14th, 2022
- Efficacy of Neoadjuvant Immunotherapy on Breast Cancer is Independent of Race - Pharmacy Times - August 14th, 2022
- Your True Age Might Not Be Your Birthdate And Thats Good News - Goalcast - August 14th, 2022
- Epigenetics Market is Predicted to Hit $6460.5 Million Value by 2030, says P&S Intelligence - PR Newswire UK - July 27th, 2022
- ORYZON Collaborates with the CMT Research Foundation in the US - Yahoo Finance - July 27th, 2022
- What is schizophrenia? Common myths and misconceptions around the mental illness - The Mirror - July 27th, 2022
- What gene changes and blood could tell us about the opioid crisis - UCI News - July 19th, 2022
- Epigenetics Is The Key To Treating Complex Diseases; Dr. Nirmalya Saha Is Using It To Unlock Cancer Treatment And More - EconoTimes - July 19th, 2022
- Heatstroke stresses the body years after the original heat illness - University of Florida - July 19th, 2022
- Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma... - July 19th, 2022
- Genetics proposes, epigenetics disposes: how our approach to human health changes in the 21st century and how CRISPR-Cas is involved - Digital Journal - June 22nd, 2022
- The relationship between P16INK4A and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand |... - June 22nd, 2022
- Omega Therapeutics (OMGA) Research Analysts' Weekly Ratings Changes - Defense World - June 13th, 2022
- Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D - Business Wire - June 13th, 2022
- Plant biologist nominated for prestigious early career award - University of Georgia - June 13th, 2022
- Julee Cruise's Career: How and where to watch Twin Peaks and all her TV appearances - Bolavip US - June 13th, 2022
- Hitting the Pro Race Track: Onovi Health Adds Marko Radiic, Professional Race Car Driver & Entrepreneur, as a Brand Ambassador - PR Newswire - June 13th, 2022
- Epigenetics: Definition & Examples | Live Science - June 4th, 2022
- Genetics and Epigenetics of Addiction DrugFacts | National Institute on ... - June 4th, 2022
- Epigenetics Market is Growing Rapidly with Recent Demand, Trends, Development, Revenue and Forecast to 2029 The Greater Binghamton Business Journal -... - June 4th, 2022
- Epigenetics at the Intersection of COVID-19 Risk and Environmental Chemical Exposures - DocWire News - June 4th, 2022
- Global Epigenetics Instrument Market 2022 Covid 19 Impact on Top countries data |Illumina, Thermo Fisher, Diagenode The Greater Binghamton Business... - June 4th, 2022
- Global Biomarkers Market Outlook & Forecast 2022-2027: Increase In Number of Pipeline Biomarkers & Rising Adoption of Biomarkers In Disease... - June 4th, 2022
- Many African Americans face unresolved trauma of racism and enslavement; It's affecting their health - ideastream - June 4th, 2022
- Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial - BioSpace - May 15th, 2022
- Gene edited rats cured of anxiety and alcoholism | SYFY WIRE - Syfy - May 15th, 2022
- Dreams on Fire sheds light on epigenetics, collective trauma of genocide traveling through generations - Armenian Weekly - May 2nd, 2022
- NEAR science: good for what ails stressed communities - NUjournal - May 2nd, 2022
- Digital biomarkers - An Emerging tool in precision Medicines. The Biomarkers Market to Reach $86 Billion by 2027 - Arizton - Yahoo Finance - May 2nd, 2022
- Sprint Bioscience's NIMA program is focused on the target protein NNMT and will be launched at the BIO International convention - Marketscreener.com - May 2nd, 2022
- Post-Doctoral Associate in the Center for Genomics and Systems Biology job with NEW YORK UNIVERSITY ABU DHABI | 291713 - Times Higher Education - May 2nd, 2022
- Womb with a View: On the Science of Maternal Effects - lareviewofbooks - April 19th, 2022
- Molecular Biology Enzymes, Kits & Reagents Market likely to bring in approximately US$ 22000 Million revenues by 2026-end Political Beef -... - April 19th, 2022
- Type 2 diabetes on the rise among Wisconsin children - Iron Mountain Daily News - April 19th, 2022
- January 2022: Exposures, diverse populations, and epigenetics merge in grantee's lab - Environmental Factor Newsletter - January 5th, 2022
- Research Roundup: Why mRNA Vaccines are So Good Against Severe COVID-19 and More - BioSpace - January 5th, 2022
- Epigenetics - Genome.gov - December 24th, 2021
- Genetics, Epigenetics, and Cancer: What Data Are We Missing? - AJMC.com Managed Markets Network - December 24th, 2021
- Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19? - DocWire News - December 24th, 2021
- Genomics Market Revenue to Cross US$ 49996.15 by 2027: The Insight Partners - Digital Journal - December 24th, 2021
- Hydra regrow their heads and live forever due to epigenetics - Cosmos Magazine - December 10th, 2021
- Epigenetics Market to Garner US$ 2611.57 MN, Globally, by 2025 at 13.6% CAGR: The Insight Partners - Digital Journal - December 10th, 2021
- Research Associate or Research Assistant in Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 274309 - Times Higher Education (THE) - December 10th, 2021
- Newpath Commits $350 Million to Fund the Next Good Things in the Life Sciences - BioSpace - December 10th, 2021
- Wind Turbine Market Development Overview And Analysis Till 2030- Market.Biz - Digital Journal - December 10th, 2021
- Cancer Testing Product Market to Witness Growth Acceleration | Epigenetics Ag, Techlab, Positive Bioscience Energy Siren - Energy Siren - November 22nd, 2021
- How can students make the best of their anxiety? - The Medium - November 22nd, 2021
- Epigenetic Study Links Smoke Exposure in Early Life to Advanced Aging - WhatIsEpigenetics.com - October 28th, 2021
- Salarius Pharmaceuticals (SLRX) is Developing a Novel LSD1 Inhibitor, Positioning it as a Significant Mover in Epigenetics-Based Cancer Therapies -... - October 28th, 2021
- Epigenetics-Based Kits Market To Witness High Growth In Near Future IMIESA - IMIESA - October 28th, 2021
- Epigenetics Diagnostic Market to Witness Growth Acceleration | Qiagen, Abcam plc, Novartis AG, Thermo Fisher Scientific IMIESA - IMIESA - October 28th, 2021
- LXRepair, Gustave Roussy Ink Research Partnership in Personalized Radiotherapy - Precision Oncology News - October 28th, 2021
- Van Andel Institute, Maine Medical Center Research Institute scientists earn $9.6 million Transformative Research Award from National Institutes of... - October 5th, 2021
- Epigenetics could reveal if you had a 'vanishing twin' - Popular Science - October 5th, 2021
- Epigenetics: Conducting The Symphony Of Genetics - Forbes - August 5th, 2021